Bioporto ASFRA:2P4 -2.26%66 Days Payable is 979.80 as of Dec. 2025, which is 457% above its 10-year median of 175.82. GuruFocus rates FRA:2P4 with a GF Score™ of 66/100 and a GF Value™ of €0.15. The stock has 3 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Bioporto AS ranks better than 87.37% on this metric.
The historical rank and industry rank for Bioporto AS's Days Payable or its related term are showing as below:
FRA:2P4'
s Days Payable Range Over the Past 10 Years
Min: 86.98 Med: 175.82 Max: 467.49
Current: 305.38
During the past 13 years, Bioporto AS's highest Days Payable was 467.49. The lowest was 86.98. And the median was 175.82.
FRA:2P4's Days Payable is ranked better than 87.37% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs FRA:2P4: 305.38
Bioporto AS's Days Payable
increased
from Dec. 2024 (154.11) to Dec. 2025 (979.80).
It may suggest that Bioporto ASdelayed paying its suppliers.
Bioporto AS Days Payable Related Terms
Bioporto AS Days Payable Historical Data
* Premium members only.
The historical data trend for Bioporto AS's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2P4 vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Bioporto AS's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's Days Payable distribution charts can be found below:
* The bar in red indicates where Bioporto AS's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bioporto AS's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioporto AS (FRA:2P4) has a Days Payable of 979.80 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bioporto AS and its competitors. This is 457% above median its historical median of 175.82. Over the past decade, Bioporto AS's Days Payable has ranged from 86.98 to 467.49. According to the industry distribution chart, Bioporto AS ranks #24 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 12.6%.
Is Bioporto AS's Days Payable too high?
Bioporto AS's current Days Payable of 979.80 is 457% above median its 10-year median of 175.82. Over the past 10 years, this metric has ranged from a low of 86.98 to a high of 467.49. The Medical Diagnostics & Research industry median Days Payable is 67.28. Bioporto AS's value of 979.80 is 1356.4% above this industry median. Based on the distribution chart, Bioporto AS ranks #24 out of 190 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Bioporto AS has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #24 out of 190 companies for Days Payable. This places Bioporto AS in the top 13% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.28. Bioporto AS's value of 979.80 is 1356.4% above this benchmark. Historically, Bioporto AS's own Days Payable has ranged from 86.98 to 467.49 over the past decade. While the company's 10-year median is 175.82 vs. the industry median of 67.28, Bioporto AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioporto AS's current Days Payable of 979.80 is 1356.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current Days Payable is 979.80, which is 457% above median its own 10-year median of 175.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (FRA:2P4) has a current Days Payable of 979.80. The stock's GF Value™ is €0.15, compared to a current price of €0.13 — trading 13.7% below its estimated fair value. The current Days Payable is 979.80, which is 457% above median its 10-year median of 175.82 and 1356.4% above the Medical Diagnostics & Research industry median of 67.28. Bioporto AS's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bioporto AS (FRA:2P4), the current Days Payable is 979.80 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (FRA:2P4) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of €0.13 is trading 13.7% below its estimated GF Value™ of €0.15.
Key valuation signals for FRA:2P4:
Days Payable: 979.80 (457% above median its 10-year median of 175.82)
GF Value™: €0.15 vs. price of €0.13 (13.7% below fair value)
Industry Position: 1356.4% above the Medical Diagnostics & Research median (#24 of 190)
No single metric tells the full story. See the FRA:2P4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
66GF Score
Get the complete analysis for FRA:2P4
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2P4 has been successfully added to your 
